Pompano Beach, FL -- (SBWIRE) -- 12/11/2012 -- CEL-SCI Corporation (NYSE:CVM) is currently trading at $0.291, 0.21% higher. CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
Will CVM Continue to Jump? Get Our Special Report To Get complete technical analysis on CVM go click my link
New Gold Inc. (USA) (NYSE:NGD) fell 1.53% to $10.92. New Gold Inc. is engaged in gold mining and related activities, including acquisition, exploration, extraction, processing and reclamation. Its operating assets consist of the Mesquite gold mine (Mesquite Mine) in the United States, the Cerro San Pedro gold-silver mine (Cerro San Pedro Mine) in Mexico, and the Peak gold-copper mines in Australia. It also consists of exploration and development projects, which include the New Afton copper-gold project in Canada, a 30% interest in the El Morro project in Chile and the Blackwater project in Canada.
Get Free Trend Analysis on NGD go click my link
Golden Star Resources Ltd. (USA) (NYSE:GSS) is lower 0.55% to $1.81. Golden Star Resources Ltd, (Golden Star) is an international gold mining and exploration company producing gold in Ghana, West Africa. The Company also conduct gold exploration in other countries in West Africa and in South America. Golden Star owns controlling interests in several gold properties in southwest Ghana. Through a 90% owned subsidiary, Golden Star (Bogoso/Prestea) Limited (GSBPL), it owns and operates the Bogoso/Prestea gold mining and processing operations (Bogoso/Prestea) located near the town of Bogoso, Ghana.
To Get complete technical analysis on GSS go click my link
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) among the losers and the stock fell 5.06% to $0.287. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials.
Get Free Trend Analysis on RNN go click my link
Inovio Pharmaceuticals, Inc. (NYSE:INO) is lower 1.50% to $0.473. Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV).
To Get complete technical analysis on INO go click my link
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)